Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for COO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for COO and 80,000+ other tickers.
See exactly how COO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for COO and 80,000+ other tickers.
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas…
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for The Cooper Companies (COO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended July 2026.
Revenue: Record revenue of $47 billion, up 58% year-over-year.Earnings Per Share (EPS): Record diluted non-GAAP EPS of $7.04, up 203%.Gross Margin: Gross margin
The transaction involved 22,559 shares with a total estimated value of ~$1.0 million based on weighted average pricing. The sale represented 3% of the total equity holdings held directly by the executive prior to this filing.
The disposal of 9,038 shares was executed at a weighted average price of $16.79 per share, totaling ~$152,000. The transaction reduced the insider's direct equity position by 3% of previous holdings.
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both The Cooper Companies (COO) and Merit Medical (MMSI). But which of these two stocks is more attractive to value investors?